PedAM
Pediatric Disease Annotations & Medicines
| paresthesia | ||||
| Disease ID | 1366 |
|---|---|
| Disease | paresthesia |
| Definition | Subjective cutaneous sensations (e.g., cold, warmth, tingling, pressure, etc.) that are experienced spontaneously in the absence of stimulation. |
| Synonym | [d]paraesthesia [d]paraesthesia (situation) [d]paresthesia [d]paresthesia (context-dependent category) [d]paresthesia (situation) abnormal sensation paraesthesia paraesthesia (numbness/tingling) paraesthesias parasthesia parasthesias paresthesia (finding) paresthesia (numbness/tingling) paresthesia [disease/finding] paresthesias |
| UMLS | C0030554 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:27) C0442874 | neuropathy | 6 C0031117 | peripheral neuropathy | 2 C0700594 | radiculopathy | 2 C0037317 | sleep disturbance | 2 C0020456 | hyperglycemia | 1 C0022116 | ischemia | 1 C0024236 | lymphedema | 1 C0017675 | glossitis | 1 C0006413 | burkitt's lymphoma | 1 C0037317 | sleep disturbances | 1 C0006142 | breast cancer | 1 C0025289 | meningitis | 1 C0011649 | dermoid | 1 C0031030 | apical periodontitis | 1 C1510429 | entrapment neuropathy | 1 C0031099 | periodontitis | 1 C0155934 | acute apical periodontitis | 1 C0002170 | alopecia | 1 C0043019 | wallenberg's syndrome | 1 C0029443 | osteomyelitis | 1 C0021775 | intermittent claudication | 1 C0024299 | lymphoma | 1 C0011882 | diabetic neuropathy | 1 C0014804 | erythromelalgia | 1 C0040034 | thrombocytopenia | 1 C0547030 | visual disturbance | 1 C0015230 | rash | 1 |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:2) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 1366 |
|---|---|
| Disease | paresthesia |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:1) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:53) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHR | POS | SNPID | REF | ALT | ORI_SNPID | PMID | P_VALUE | P_VALUE_TEXT | OR/BETA | CI95_TEXT | GWAS_INITIAL_SAMPLE_SIZE | SUB_POPULATION | SUPER_POPULATION | GWAS_TRAIT | HPO_ID | HPO_TERM | DO_ID | DO_TERM | MESH_ID | MESH_TERM | EFO_ID | EFO_TERM | DOLITE_TERM | RISK_ALLELE | PUBLICATION_TYPE | AA | GENE_SYMBOL | TYPE | REFGENE |
| 1 | 54061333 | rs7551844 | T | C | rs7551844 | 23834954 | 2.14E-04 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 1 | 110405271 | rs6537883 | T | C | rs6537883 | 23834954 | 3.00E-06 | Hypoesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 1 | 199519005 | rs945877 | G | A | rs945877 | 23834954 | 4.07E-05 | dysesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 1 | 241945917 | rs4658506 | C | T | rs4658506 | 23834954 | 1.06E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 1 | 248039294 | rs1339847 | G | A | rs1339847 | 23834954 | 1.99E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 2 | 80529956 | rs6733871 | T | C | rs6733871 | 23834954 | 4.69E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 2 | 183336468 | rs10497603 | T | C | rs10497603 | 23834954 | 5.11E-04 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 3 | 102203045 | rs2063640 | C | A | rs2063640 | 23834954 | 2.00E-06 | Hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 4 | 5110140 | rs6833812 | G | A | rs6833812 | 23834954 | 7.00E-06 | Hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 4 | 8549845 | rs10805209 | C | T | rs10805209 | 23834954 | 2.12E-04 | dysesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 4 | 36490815 | rs6829274 | C | T | rs6829274 | 23834954 | 3.91E-05 | dysesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 4 | 102002123 | rs3804357 | C | A | rs3804357 | 23834954 | 1.12E-05 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 4 | 177916874 | rs13110230 | T | G | rs13110230 | 23834954 | 1.36E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 5 | 84167824 | rs4235662 | T | C | rs4235662 | 23834954 | 1.05E-05 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 5 | 110504115 | rs1072056 | C | A | rs1072056 | 23834954 | 1.06E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 5 | 180513467 | rs730545 | G | A | rs730545 | 23834954 | 8.05E-05 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 6 | 13634982 | rs707816 | C | T | rs707816 | 23834954 | 2.99E-04 | hypoesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 6 | 52598501 | rs9474312 | C | T | rs9474312 | 23834954 | 2.18E-05 | hypoesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 6 | 156868948 | rs502281 | G | A | rs502281 | 23834954 | 6.63E-07 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 6 | 156904256 | rs1998930 | A | G | rs1998930 | 23834954 | 9.94E-06 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 6 | 156913012 | rs2817461 | G | A | rs2817461 | 23834954 | 4.00E-08 | Hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 7 | 17318312 | rs13236243 | G | A | rs13236243 | 23834954 | 4.00E-06 | Hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 8 | 27994241 | rs4732828 | T | G | rs4732828 | 23834954 | 9.31E-05 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 8 | 69895021 | rs7825569 | C | T | rs7825569 | 23834954 | 9.14E-05 | dysesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 8 | 135007667 | rs6982411 | C | T | rs6982411 | 23834954 | 7.46E-05 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 9 | 7174673 | rs913588 | G | A | rs913588 | 23834954 | 9.56E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 9 | 109265076 | rs6477523 | G | T | rs6477523 | 23834954 | 2.28E-04 | dysesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 9 | 109382361 | rs9942977 | G | A | rs9942977 | 23834954 | 1.13E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 9 | 110765359 | rs10512369 | G | A | rs10512369 | 23834954 | 1.06E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 11 | 40819106 | rs10837504 | C | A | rs10837504 | 23834954 | 1.65E-04 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 11 | 97643824 | rs1960997 | T | C | rs1960997 | 23834954 | 6.38E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 11 | 119502477 | rs1567375 | A | C | rs1567375 | 23834954 | 1.31E-05 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 11 | 122851563 | rs1870761 | C | A | rs1870761 | 23834954 | 6.79E-05 | hypoesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 12 | 6457062 | rs2228576 | T | C | rs2228576 | 23834954 | 8.60E-05 | hypoesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 12 | 10170161 | rs1054611 | G | T | rs1054611 | 23834954 | 6.00E-06 | Hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 12 | 22051296 | rs10841907 | T | G | rs10841907 | 23834954 | 1.10E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 12 | 57489709 | rs1059513 | T | C | rs1059513 | 23834954 | 7.00E-06 | Hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 13 | 52194944 | rs9535720 | T | C | rs9535720 | 23834954 | 6.56E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 14 | 65119676 | rs4902304 | C | T | rs4902304 | 23834954 | 3.15E-05 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 14 | 65400265 | rs1064108 | C | T | rs1064108 | 23834954 | 1.07E-04 | dysesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 15 | 73933718 | rs1564492 | A | G | rs1564492 | 23834954 | 1.06E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 16 | 71254941 | rs236008 | C | T | rs236008 | 23834954 | 2.48E-04 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 17 | 14988987 | rs12603925 | A | G | rs12603925 | 23834954 | 4.56E-04 | dysesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 18 | 2547500 | rs2677879 | G | T | rs2677879 | 23834954 | 4.72E-05 | dysesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 18 | 42612091 | rs10502849 | C | T | rs10502849 | 23834954 | 9.41E-05 | hypoesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 18 | 42620533 | rs7228266 | G | A | rs7228266 | 23834954 | 1.21E-05 | hypoesthesia, Trend | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 19 | 33047114 | rs2868145 | A | G | rs2868145 | 23834954 | 1.06E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 20 | 3735601 | rs2295343 | A | G | rs2295343 | 23834954 | 8.41E-05 | hypoesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 20 | 10129600 | rs2210585 | A | G | rs2210585 | 23834954 | 2.28E-05 | dysesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 21 | 27969859 | rs395640 | A | G | rs395640 | 23834954 | 1.36E-04 | hypoesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 21 | 44761874 | rs2838271 | G | A | rs2838271 | 23834954 | 2.88E-04 | dysesthesia, Recessive | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 21 | 47786524 | rs2839227 | A | G | rs2839227 | 23834954 | 2.93E-04 | hypoesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
| 22 | 44581046 | rs139131 | C | T | rs139131 | 23834954 | 6.78E-05 | hypoesthesia, Dominant | NA | NA | Up to 105 individuals | NOPOP(105) | ALL(105) | NOPOP(105) | ALL(105) | Sensory disturbances after bilateral sagittal split ramus osteotomy | HPOID:0003401 | Paresthesia | DOID:1491 | DOID:0050155 | corneal anesthesia and hypoesthesia | sensory system disease | NA | NA | NA | NA | Nervous system disease | Corneal disease | NA |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:71) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0030554 | amifostine | D004999 | 20537-88-6 | paresthesia | MESH:D010292 | marker/mechanism | 10955873 | ||
| C0030554 | amifostine | D004999 | 20537-88-6 | paresthesia | MESH:D010292 | therapeutic | 14514973 | ||
| C0030554 | amitriptyline | D000639 | 50-48-6 | paresthesia | MESH:D010292 | marker/mechanism | 2833464 | ||
| C0030554 | amitriptyline | D000639 | 50-48-6 | paresthesia | MESH:D010292 | therapeutic | 7904620 | ||
| C0030554 | bleomycin | D001761 | 11056-06-7 | paresthesia | MESH:D010292 | marker/mechanism | 2476531 | ||
| C0030554 | bortezomib | D000069286 | - | paresthesia | MESH:D010292 | marker/mechanism | 19259673 | ||
| C0030554 | bupivacaine | D002045 | 2180-92-9 | paresthesia | MESH:D010292 | marker/mechanism | 10853229 | ||
| C0030554 | buspirone | D002065 | 36505-84-7 | paresthesia | MESH:D010292 | marker/mechanism | 2870641 | ||
| C0030554 | capsaicin | D002211 | 404-86-4 | paresthesia | MESH:D010292 | marker/mechanism | 2458561 | ||
| C0030554 | carbamazepine | D002220 | 298-46-4 | paresthesia | MESH:D010292 | therapeutic | 11360270 | ||
| C0030554 | carmustine | D002330 | 154-93-8 | paresthesia | MESH:D010292 | marker/mechanism | 9134180 | ||
| C0030554 | ciprofloxacin | D002939 | 85721-33-1 | paresthesia | MESH:D010292 | marker/mechanism | 7488901 | ||
| C0030554 | citalopram | D015283 | 59729-33-8 | paresthesia | MESH:D010292 | marker/mechanism | 17092960 | ||
| C0030554 | clonidine | D003000 | 4205-90-7 | paresthesia | MESH:D010292 | marker/mechanism | 10777003 | ||
| C0030554 | cyclophosphamide | D003520 | 50-18-0 | paresthesia | MESH:D010292 | marker/mechanism | 11401310 | ||
| C0030554 | cyclosporine | D016572 | 59865-13-3 | paresthesia | MESH:D010292 | marker/mechanism | 3544376 | ||
| C0030554 | cisplatin | D002945 | 15663-27-1 | paresthesia | MESH:D010292 | marker/mechanism | 11104554 | ||
| C0030554 | zalcitabine | D016047 | 7481-89-2 | paresthesia | MESH:D010292 | marker/mechanism | 7853984 | ||
| C0030554 | disopyramide | D004206 | 3737/9/5 | paresthesia | MESH:D010292 | marker/mechanism | 11865156 | ||
| C0030554 | doxycycline | D004318 | 564-25-0 | paresthesia | MESH:D010292 | marker/mechanism | 5026677 | ||
| C0030554 | enalapril | D004656 | 75847-73-3 | paresthesia | MESH:D010292 | marker/mechanism | 1336423 | ||
| C0030554 | epirubicin | D015251 | 56420-45-2 | paresthesia | MESH:D010292 | marker/mechanism | 12125951 | ||
| C0030554 | ethambutol | D004977 | 74-55-5 | paresthesia | MESH:D010292 | marker/mechanism | 24897009 | ||
| C0030554 | fluorouracil | D005472 | 51-21-8 | paresthesia | MESH:D010292 | marker/mechanism | 12963697 | ||
| C0030554 | fluoxetine | D005473 | 54910-89-3 | paresthesia | MESH:D010292 | marker/mechanism | 2356884 | ||
| C0030554 | leucovorin | D002955 | 1958/5/9 | paresthesia | MESH:D010292 | marker/mechanism | 12963697 | ||
| C0030554 | foscarnet | D017245 | 4428-95-9 | paresthesia | MESH:D010292 | marker/mechanism | 7803878 | ||
| C0030554 | fosphenytoin | C043114 | 93390-81-9 | paresthesia | MESH:D010292 | marker/mechanism | 12500711 | ||
| C0030554 | gabapentin | C040029 | 60142-96-3 | paresthesia | MESH:D010292 | therapeutic | 11027910 | ||
| C0030554 | gemcitabine | C056507 | 103882-84-4 | paresthesia | MESH:D010292 | marker/mechanism | 10955861 | ||
| C0030554 | griseofulvin | D006118 | 126-07-8 | paresthesia | MESH:D010292 | marker/mechanism | 1967699 | ||
| C0030554 | ifosfamide | D007069 | 3778-73-2 | paresthesia | MESH:D010292 | marker/mechanism | 11568902 | ||
| C0030554 | labetalol | D007741 | 36894-69-6 | paresthesia | MESH:D010292 | marker/mechanism | 293566 | ||
| C0030554 | lansoprazole | D064747 | - | paresthesia | MESH:D010292 | marker/mechanism | 15468341 | ||
| C0030554 | lidocaine | D008012 | 137-58-6 | paresthesia | MESH:D010292 | marker/mechanism | 10994828 | ||
| C0030554 | lidocaine | D008012 | 137-58-6 | paresthesia | MESH:D010292 | therapeutic | 19489054 | ||
| C0030554 | lindane | D001556 | 58-89-9 | paresthesia | MESH:D010292 | marker/mechanism | 2459503 | ||
| C0030554 | lovastatin | D008148 | 75330-75-5 | paresthesia | MESH:D010292 | marker/mechanism | 7484806 | ||
| C0030554 | mefloquine | D015767 | 53230-10-7 | paresthesia | MESH:D010292 | marker/mechanism | 1443980 | ||
| C0030554 | methotrexate | D008727 | 1959/5/2 | paresthesia | MESH:D010292 | marker/mechanism | 21064136 | ||
| C0030554 | metoprolol | D008790 | 37350-58-6 | paresthesia | MESH:D010292 | marker/mechanism | 293566 | ||
| C0030554 | midodrine | D008879 | 42794-76-3 | paresthesia | MESH:D010292 | marker/mechanism | 9398120 | ||
| C0030554 | mirtazapine | C035133 | - | paresthesia | MESH:D010292 | marker/mechanism | 12530413 | ||
| C0030554 | levonorgestrel | D016912 | 797-63-7 | paresthesia | MESH:D010292 | marker/mechanism | 7852942 | ||
| C0030554 | omeprazole | D009853 | 73590-58-6 | paresthesia | MESH:D010292 | marker/mechanism | 2265010 | ||
| C0030554 | oxaliplatin | C030110 | - | paresthesia | MESH:D010292 | marker/mechanism | 12963697 | ||
| C0030554 | paclitaxel | D017239 | - | paresthesia | MESH:D010292 | marker/mechanism | 10483822 | ||
| C0030554 | pefloxacin | D015366 | 70458-92-3 | paresthesia | MESH:D010292 | marker/mechanism | 1352007 | ||
| C0030554 | phenytoin | D010672 | 57-41-0 | paresthesia | MESH:D010292 | marker/mechanism | 10219285 | ||
| C0030554 | pravastatin | D017035 | 81093-37-0 | paresthesia | MESH:D010292 | marker/mechanism | 10027656 | ||
| C0030554 | propranolol | D011433 | 525-66-6 | paresthesia | MESH:D010292 | marker/mechanism | 699788 | ||
| C0030554 | pyridoxine | D011736 | - | paresthesia | MESH:D010292 | marker/mechanism | 14687374 | ||
| C0030554 | pyridoxine | D011736 | - | paresthesia | MESH:D010292 | therapeutic | 18191705 | ||
| C0030554 | rifampin | D012293 | 13292-46-1 | paresthesia | MESH:D010292 | marker/mechanism | 673833 | ||
| C0030554 | ropivacaine | C037663 | 84057-95-4 | paresthesia | MESH:D010292 | marker/mechanism | 9175963 | ||
| C0030554 | sulfisoxazole | D013444 | 127-69-5 | paresthesia | MESH:D010292 | marker/mechanism | 6849452 | ||
| C0030554 | sulindac | D013467 | 38194-50-2 | paresthesia | MESH:D010292 | marker/mechanism | 6093724 | ||
| C0030554 | temazepam | D013693 | 846-50-4 | paresthesia | MESH:D010292 | marker/mechanism | 2884682 | ||
| C0030554 | temozolomide | C047246 | 85622-93-1 | paresthesia | MESH:D010292 | marker/mechanism | 17495388 | ||
| C0030554 | thalidomide | D013792 | 50-35-1 | paresthesia | MESH:D010292 | marker/mechanism | 10918274 | ||
| C0030554 | tinidazole | D014011 | 19387-91-8 | paresthesia | MESH:D010292 | marker/mechanism | 7123 | ||
| C0030554 | tretinoin | D014212 | 302-79-4 | paresthesia | MESH:D010292 | marker/mechanism | 10203107 | ||
| C0030554 | valproic acid | D014635 | 99-66-1 | paresthesia | MESH:D010292 | marker/mechanism | 6772435 | ||
| C0030554 | vancomycin | D014640 | 1404-90-6 | paresthesia | MESH:D010292 | marker/mechanism | 2976372 | ||
| C0030554 | vinblastine | D014747 | 865-21-4 | paresthesia | MESH:D010292 | marker/mechanism | 11104554 | ||
| C0030554 | vincristine | D014750 | - | paresthesia | MESH:D010292 | marker/mechanism | 10499201 | ||
| C0030554 | vincristine | D014750 | - | paresthesia | MESH:D010292 | therapeutic | 8534764 | ||
| C0030554 | vindesine | D014751 | 53643-48-4 | paresthesia | MESH:D010292 | marker/mechanism | 6249481 | ||
| C0030554 | vinorelbine | C030852 | 71486-22-1 | paresthesia | MESH:D010292 | marker/mechanism | 15493354 | ||
| C0030554 | vitamin e | D014810 | 1406-18-4 | paresthesia | MESH:D010292 | marker/mechanism | 10453775 | ||
| C0030554 | zidovudine | D015215 | 30516-87-1 | paresthesia | MESH:D010292 | marker/mechanism | 7853984 | ||
FDA approved drug and dosage information(Total Drugs:35) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D010292 | neurontin | gabapentin | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D010292 | neurontin | gabapentin | 600MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D010292 | neurontin | gabapentin | 250MG/5ML | SOLUTION;ORAL | Prescription | AA | Yes | Yes |
| MESH:D010292 | neurontin | gabapentin | 0 | SOLUTION; ORAL | Prescription | None | No | No |
| MESH:D010292 | neurontin | gabapentin | 600MG | TABLET; ORAL | Prescription | None | No | No |
| MESH:D010292 | neurontin | gabapentin | 800MG | CAPSULE; ORAL | Prescription | None | No | No |
| MESH:D010292 | neurontin | gabapentin | 250MG/5ML | SOLUTION; ORAL | Prescription | None | No | No |
| MESH:D010292 | mevacor | lovastatin | 10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | TABLET;ORAL | Discontinued | None | Yes | No |
| MESH:D010292 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D010292 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D010292 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
| MESH:D010292 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
| MESH:D010292 | temodar | temozolomide | 5MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D010292 | temodar | temozolomide | 100MG/VIAL | POWDER;INTRAVENOUS | Prescription | None | Yes | Yes |
| MESH:D010292 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D010292 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
| MESH:D010292 | prevacid | lansoprazole | 15MG | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription | AB | Yes | No |
| MESH:D010292 | prevacid | lansoprazole | 15MG/PACKET | FOR SUSPENSION, DELAYED RELEASE;ORAL | Discontinued | None | No | No |
| MESH:D010292 | prevacid | lansoprazole | 15MG | TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL | Prescription | None | Yes | No |
| MESH:D010292 | prevacid | lansoprazole | 15MG | CAPSULE, DELAYED REL PELLETS;ORAL | Prescription | AB | Yes | No |
| MESH:D010292 | prevacid | lansoprazole | 15MG/PACKET | FOR SUSPENSION, DELAYED RELEASE;ORAL | Discontinued | None | No | No |
| MESH:D010292 | prevacid | lansoprazole | 15MG | TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL | Prescription | None | Yes | No |
| MESH:D010292 | remeron | mirtazapine | 15MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
| MESH:D010292 | eloxatin | oxaliplatin | 50MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | INJECTABLE;IV (INFUSION) | Discontinued | None | Yes | No |
| MESH:D010292 | eloxatin | oxaliplatin | 50MG/10ML (5MG/ML) | INJECTABLE;IV (INFUSION) | Prescription | AP | Yes | Yes |
| MESH:D010292 | oxaliplatin | oxaliplatin | 50MG/10ML (5MG/ML) | INJECTABLE;IV (INFUSION) | Prescription | AP | Yes | Yes |
| MESH:D010292 | mirena | levonorgestrel | 52MG | INTRAUTERINE DEVICE;INTRAUTERINE | Prescription | None | Yes | Yes |
| MESH:D010292 | levonorgestrel | levonorgestrel | 75MG/IMPLANT | IMPLANT;IMPLANTATION | Discontinued | None | No | No |
| MESH:D010292 | retrovir | zidovudine | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | Yes |
| MESH:D010292 | retrovir | zidovudine | 50MG/5ML | SYRUP;ORAL | Prescription | AA | Yes | Yes |
| MESH:D010292 | retrovir | zidovudine | 10MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
| MESH:D010292 | retrovir | zidovudine | 200MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D010292 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D010292 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D010292 | velcade | bortezomib | 3.5MG/VIAL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:35) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D010292 | 12/10/2000 | neurontin | gabapentin | Adjunctive therapy in the treatment of partial seizures | Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children | Labeling | B | - | - | - | Parke-Davis | 2/2/2000 | FALSE' |
| MESH:D010292 | 12/10/2000 | neurontin | gabapentin | Adjunctive therapy in the treatment of partial seizures | Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children | Labeling | B | - | - | - | Parke-Davis | 2/2/2000 | FALSE' |
| MESH:D010292 | 12/10/2000 | neurontin | gabapentin | Adjunctive therapy in the treatment of partial seizures | Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children | Labeling | B | - | - | - | Parke-Davis | 2/2/2000 | FALSE' |
| MESH:D010292 | 12/10/2000 | neurontin | gabapentin | Adjunctive therapy in the treatment of partial seizures | Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children | Labeling | B | - | - | - | Parke-Davis | 2/2/2000 | FALSE' |
| MESH:D010292 | 12/10/2000 | neurontin | gabapentin | Adjunctive therapy in the treatment of partial seizures | Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children | Labeling | B | - | - | - | Parke-Davis | 2/2/2000 | FALSE' |
| MESH:D010292 | 12/10/2000 | neurontin | gabapentin | Adjunctive therapy in the treatment of partial seizures | Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children | Labeling | B | - | - | - | Parke-Davis | 2/2/2000 | FALSE' |
| MESH:D010292 | 12/10/2000 | neurontin | gabapentin | Adjunctive therapy in the treatment of partial seizures | Safety and effectiveness established down to 3 years Neuropsychiatric AE's identified in 3-12 year olds Oral clearance normalized per body weight increased in children | Labeling | B | - | - | - | Parke-Davis | 2/2/2000 | FALSE' |
| MESH:D010292 | 02/14/2002 | mevacor | lovastatin | Heterozygous Familial Hypercholesterolemia | New indication in adolescent boys and girls (at least one year post-menarche) 10-17 years of age | Labeling | B | - | - | - | Merck | 07/17/2001 | FALSE' |
| MESH:D010292 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D010292 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |
| MESH:D010292 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D010292 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |
| MESH:D010292 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
| MESH:D010292 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
| MESH:D010292 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D010292 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D010292 | 06/17/2004 | prevacid | lansoprazole | Short-term treatment of symptomatic GERD and erosive Esophagitis | Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients | Labeling | B | - | - | - | Tap | 07/15/2008 | FALSE' |
| MESH:D010292 | 06/17/2004 | prevacid | lansoprazole | Short-term treatment of symptomatic GERD and erosive Esophagitis | Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients | Labeling | B | - | - | - | Tap | 07/15/2008 | FALSE' |
| MESH:D010292 | 06/17/2004 | prevacid | lansoprazole | Short-term treatment of symptomatic GERD and erosive Esophagitis | Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients | Labeling | B | - | - | - | Tap | 07/15/2008 | FALSE' |
| MESH:D010292 | 10/28/2008 | prevacid | lansoprazole | Symptomatic GERD in infants | Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies | Labeling | - | - | B, P | - | Takeda | 07/15/2008 | FALSE' |
| MESH:D010292 | 10/28/2008 | prevacid | lansoprazole | Symptomatic GERD in infants | Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies | Labeling | - | - | B, P | - | Takeda | 07/15/2008 | FALSE' |
| MESH:D010292 | 10/28/2008 | prevacid | lansoprazole | Symptomatic GERD in infants | Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies | Labeling | - | - | B, P | - | Takeda | 07/15/2008 | FALSE' |
| MESH:D010292 | 12/1/2005 | remeron | mirtazapine | Major Depressive Disorder | Safety and effectiveness in the pediatric population have not been established FDA required boxed warning for all antidepressants: Suicidality in Children and Adolescents - Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Remeron or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Remeron is not approved for use in pediatric patients. (See Warnings and Precautions: Pediatric Use) Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials Two placebo-controlled trials in 258 pediatric patients with MDD have been conducted with Remeron and the data were not sufficient to support a claim for use in pediatric patients | Labeling | B | - | - | - | Organon | - | FALSE' |
| MESH:D010292 | 10/1/2007 | eloxatin | oxaliplatin | Solid tumors | The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs | Labeling | B | - | - | - | Sanofi-Aventis | 09/27/2006 | FALSE' |
| MESH:D010292 | 10/1/2007 | eloxatin | oxaliplatin | Solid tumors | The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs | Labeling | B | - | - | - | Sanofi-Aventis | 09/27/2006 | FALSE' |
| MESH:D010292 | 10/1/2007 | eloxatin | oxaliplatin | Solid tumors | The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs | Labeling | B | - | - | - | Sanofi-Aventis | 09/27/2006 | FALSE' |
| MESH:D010292 | 1/10/2009 | mirena | levonorgestrel-releasing intrauterine system | Treatment of heavy menstrual bleeding for women using intrauterine contraception | New indication for the treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception Use before menarche is not indicated | Labeling | - | P | - | - | Berlex | - | TRUE' |
| MESH:D010292 | 10/7/2009 | plan b one step | levonorgestrel | Emergency contraception - OTC in women 17 years and older; RX for women younger than age 17 years | New single dose 1.5 mg tablet New dosage regimen | Labeling | - | P | - | - | Duramed | - | FALSE' |
| MESH:D010292 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D010292 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D010292 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D010292 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D010292 | 09/19/2008 | retrovir syrup, capsules and tablets | zidovudine | Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection | Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D010292 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D010292 | 09/14/2015 | velcade | bortezomib | Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed | Labeling | B | - | - | - | Millennium Pharmaceuticals, Inc. | - | FALSE |